|
1
|
Bergsagel PL, Mateos MV, Gutierrez NC,
Rajkumar SV and San Miguel JF: Improving overall survival and
overcoming adverse prognosis in the treatment of cytogenetically
high-risk multiple myeloma. Blood. 121:884–892. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zaman S, Shentu S, Yang J, He J, Orlowski
RZ, Stellrecht CM and Gandhi V: Targeting the pro-survival protein
MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma
cells. Neoplasia. 17:289–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borset M, Lien E, Espevik T, Helseth E,
Waage A and Sundan A: Concomitant expression of hepatocyte growth
factor/scatter factor and the receptor c-MET in human myeloma cell
lines. J Biol Chem. 271:24655–24661. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mahtouk K, Tjin EP, Spaargaren M and Pals
ST: The HGF/MET pathway as target for the treatment of multiple
myeloma and B-cell lymphomas. Biochim Biophys Acta. 1806:208–219.
2010.PubMed/NCBI
|
|
5
|
Que W, Chen J, Chuang M and Jiang D:
Knockdown of c-Met enhances sensitivity to bortezomib in human
multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
APMIS. 120:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Que W and Chen J: Knockdown of c-Met
inhibits cell proliferation and invasion and increases
chemosensitivity to doxorubicin in human multiple myeloma U266
cells in vitro. Mol Med Rep. 4:343–349. 2011.PubMed/NCBI
|
|
7
|
Ferrucci A, Moschetta M, Frassanito MA,
Berardi S, Catacchio I, Ria R, Racanelli V, Caivano A, Solimando
AG, Vergara D, et al: A HGF/cMET autocrine loop is operative in
multiple myeloma bone marrow endothelial cells and may represent a
novel therapeutic target. Clin Cancer Res. 20:5796–5807. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizuno S and Nakamura T: HGF-MET cascade,
a key target for inhibiting cancer metastasis: The impact of NK4
discovery on cancer biology and therapeutics. Int J Mol Sci.
14:888–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Que W and Chen J: Gateway technical
supported construction of a recombinant adenovirus vector pAd-NK4.
Chinese Pharmacol Bulletin. 27:467–472. 2011.
|
|
10
|
Que W and Chen J: Ad-NK4 enhances the
chemosensitivity of human multiple myeloma RPMI 8226 cells to
bortezomib. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:1079–1085.
2016.(In Chinese). PubMed/NCBI
|
|
11
|
Deng XB, Xiao L, Wu Y, Jin F, Mossman B,
Testa JR and Xiao GH: Inhibition of mesothelioma cancer stem-like
cells with adenovirus-mediated NK4 gene therapy. Int J Cancer.
137:481–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramanujum R, Lin YL, Liu JK and He S:
Regulatory expression of MMP-8/MMP-9 and inhibition of
proliferation, migration and invasion in human lung cancer A549
cells in the presence of HGF variants. Kaohsiung J Med Sci.
29:530–539. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun YP, Zhang BL, Duan JW, Wu HH, Wang BQ,
Yu ZP, Yang WJ, Shan YF, Zhou MT and Zhang QY: Effect of NK4
transduction in bone marrow-derived mesenchymal stem cells on
biological characteristics of pancreatic cancer cells. Int J Mol
Sci. 15:3729–3745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han L, Zhang Y, Liu S, Zhao Q, Liang X, Ma
Z, Gupta PK, Zhao M and Wang A: Autophagy flux inhibition, G2/M
cell cycle arrest and apoptosis induction by ubenimex in glioma
cell lines. Oncotarget. 8:107730–107743. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lima KG, Krause GC, da Silva EFG, Xavier
LL, Martins LAM, Alice LM, da Luz LB, Gassen RB, Filippi-Chiela EC,
Haute GV, et al: Octyl gallate reduces ATP levels and Ki67
expression leading HepG2 cells to cell cycle arrest and
mitochondria-mediated apoptosis. Toxicol In Vitro. 48:11–25. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kale J, Osterlund EJ and Andrews DW: BCL-2
family proteins: Changing partners in the dance towards death. Cell
Death Differ. 25:65–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ge X, Wang Y, Li Q, Yu H, Ji G and Miao L:
NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma
cells by modulating the intrinsic apoptosis pathway. Oncol Rep.
30:448–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang T, Ji D, Wang P, Liang D, Jin L, Shi
H, Liu X, Meng Q, Yu R and Gao S: The atypical protein kinase RIOK3
contributes to glioma cell proliferation/survival,
migration/invasion and the AKT/mTOR signaling pathway. Cancer Lett.
415:151–163. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du W, Hattori Y, Yamada T, Matsumoto K,
Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T and Ikeda Y:
NK4, an antagonist of hepatocyte growth factor (HGF), inhibits
growth of multiple myeloma cells: Molecular targeting of angiogenic
growth factor. Blood. 109:3042–3049. 2007.PubMed/NCBI
|
|
20
|
Lv XY, Ma L, Chen JF, Yu R, Li Y, Yan ZJ,
Cheng Y and Ma Q: Knockdown of DUXAP10 inhibits proliferation and
promotes apoptosis in bladder cancer cells via PI3K/Akt/mTOR
signaling pathway. Int J Oncol. 52:288–294. 2018.PubMed/NCBI
|
